NCT04906746View on ClinicalTrials.gov

Ruxolitinib for Cancer Cachexia

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

September 27, 2024

Study Completion Date

December 31, 2025

Conditions
Stage IV Non-small Cell Lung CancerCachexia
Interventions
DRUG

Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.

There will be intra-patient dose escalation of ruxolitinib in every patient enrolled on study.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Tu Dan

OTHER